#ESMO26 Bispecific EGFRxHER3 targeting ADC IZA-BREN entering dynamic the #EGFR arena with the PANKU-Lung 01 trial post 3rd gen TKI:

✅ PFS 11,1 vs 5,7 m HR =0.4
✅OS NR vs 19.4 data immature
✅ ORR 60.2 vs 34.5
❌ Carbo+pem not SoC anymore , chemo+ami approved by FDA/EMA, SacTMT in FDA ( Optitrop Lung 06)
❓ How do those data compare with oncogene -driven approaches , like EGFR+MET in SAFFRON?

#ESMOAmbassadors